Design, synthesis, in vitro anticancer, molecular docking and SAR studies of new series of pyrrolo[2,3-d]pyrimidine derivatives

Table 2 MTT cell proliferation mortality assay (%) of cancer and normal cell lines at 100 μg/ml

Compound	MCF7	A549	HCT116	PC3	HePG2	PACA2	BJ1
3a	63.5 ± 2.6	3.4 ± 0.2	84.3 ± 1.1	36.5 ± 0.9	100	71.3 ± 0.8	95.3 ± 1.8
3b	11.5 ± 0.8	8.5 ± 0.6	14.6 ± 0.1	15.6 ± 1.3	10.4 ± 1.7	76.3 ± 1.8	3.5 ± 0.9
4a	100	79.4 ± 1.6	74.2 ± 2.5	53.0 ± 0.7	43.5 ± 2.2	100	74.6 ± 0.6
4b	90.3 ± 4.9	100	90.2 ± 1.0	100	84.3 ± 0.9	100	22.5 ± 0.3
5	27.9 ± 1.2	25.1 ± 0.7	60.4 ± 0.9	42.3 ± 1.3	34.5 ± 2.9	29.3 ± 0.8	16.3 ± 2.0
6	100	ND	100	100	ND	100	84.9 ± 0.7
7	100	14.2 ± 0.8	100	54.2 ± 1.6	ND	100	100
8	84.3 ± 2.5	19.3 ± 1.2	80 ± 1.0	13.5 ± 1.5	100	100	15.6 ± 2.8
9a	75.2 ± 3.6	58.6 ± 1.3	52.1 ± 0.8	53.8 ± 0.3	ND	1.3 ± 0.2	37.8 ± 0.6
9b	100	ND	45.6 ± 3.2	ND	63.8 ± 0.6	2.5 ± 0.3	ND
10	100	10.2 ± 0.5	100	100	ND	100	100
11a	65.2 ± 1.0	11.8 ± 0.6	44.2 ± 0.8	12.5 ± 1.4	7.2 ± 1.3	84.3 ± 1.7	47.3 ± 1.3
11b	80.4 ± 1.8	11.6 ± 0.9	33.5 ± 0.4	94.6 ± 1.3	63.1 ± 0.5	25.6 ± 0.9	56.9 ± 0.1
12	100	71.3 ± 1.6	64.3 ± 1.1	3.1 ± 0.2	26.3 ± 3.4	81.5 ± 1.2	100
13	3.5 ± 0.6	42.6 ± 1.2	60.2 ± 1.0	32.2 ± 1.7	12.4 ± 1.9	58.8 ± 1.2	25.3 ± 0.4
14a	100	100	100	ND	100	100	30.8 ± 0.2
14b	94.9 ± 1.1	100	100	100	100	100	ND
15	81.2 ± 0.8	84.6 ± 0.4	100	65.9 ± 2.4	100	100	4.5 ± 0.3
16a	73.6 ± 2.2	3.2 ± 0.5	73.2 ± 0.8	3.8 ± 0.3	100	7.5 ± 1.1	70.5 ± 0.4
16b	100	100	ND	ND	ND	100	ND
17	74.3 ± 1.7	89.2 ± 0.4	100	79.5 ± 0.5	100	100	12.5 ± 1.7
18a	41.2 ± 1.5	22.7 ± 0.9	54.2 ± 1.2	2.1 ± 0.6	16.4 ± 1.6	31.0 ± 1.3	3.2 ± 1.5
18b	100	11.2 ± 0.6	ND	100	100	100	20.6 ± 2.1
19	62.3 ± 3.4	5.6 ± 0.7	35.9 ± 1.5	3.7 ± 1.1	100	31.2 ± 5.1	52.7 ± 1.4
Dox	100	100	100	100	100	100	–––-
Negative control	0	0	0	0	0	0	0

ISSN: 2661-801X